TSCAN THERAPEUTICS, INC. (TCRX) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 11.71M USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 21.07M USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 171.45M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $11.71M | $21.07M | (m) | (m) | $171.45M | (m) |
| 2026-03-31 | (m) | (m) | (m) | $32.65M | (m) | (m) | $201.99M | (m) |
| 2025-12-31 | (m) | (m) | (m) | $32.53M | (m) | (m) | $228.79M | (m) |
| 2025-09-30 | (m) | (m) | (m) | $32.41M | (m) | $184.45M | $262.23M | (m) |
| 2025-06-30 | (m) | (m) | (m) | $32.30M | (m) | $218.04M | $298.56M | (m) |
| 2025-03-31 | (m) | (m) | (m) | $32.18M | (m) | $251.69M | $332.71M | (m) |
| 2024-12-31 | (m) | (m) | (m) | $32.07M | (m) | $290.11M | $371.12M | (m) |
| 2024-09-30 | (m) | (m) | (m) | $30.65M | (m) | $271.12M | $348.03M | (m) |
| 2024-06-30 | (m) | (m) | $10.34M | $20.11M | (m) | $297.68M | $374.87M | (m) |
| 2024-03-31 | (m) | (m) | $6.80M | $23.45M | (m) | $162.78M | $240.83M | (m) |
| 2023-12-31 | (m) | (m) | $3.35M | $26.70M | (m) | $192.04M | $272.15M | (m) |
| 2023-09-30 | (m) | (m) | $1.11M | $28.84M | (m) | $215.42M | $291.38M | (m) |
| 2023-06-30 | (m) | (m) | (m) | $29.72M | (m) | (m) | $316.92M | (m) |
| 2023-03-31 | (m) | (m) | (m) | $29.50M | (m) | (m) | $173.58M | (m) |
| 2022-12-31 | (m) | (m) | (m) | $29.29M | (m) | (m) | $199.09M | (m) |
| 2022-09-30 | (m) | (m) | (m) | $29.07M | (m) | (m) | $165.45M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B |